Conferences

ecancer travels so that you don't have to. Expore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

ASH 2014

6 - 9 Dec 2014
Moscone Center, San Francisco, CA, United States of America
CLL at ASH 2014: Expert discussion
Prof John Gribben and Prof Stephan Stilgenbauer
CLL at ASH 2014: Expert discussion ( Prof John Gribben and Prof Stephan Stilgenbauer )
12 Dec 2014
Examining cell-free DNA provides non-invasive detection of malignancies in Hodgk...
Dr Peter Vandenberghe - Universitair Ziekenhuis Leuven, Leuven, Belgium
Examining cell-free DNA provides non-invasive detection of malignancies in Hodgkin lymphoma ( Dr Peter Vandenberghe - Universitair Ziekenhuis Leuven, Leuven, Belgium )
12 Dec 2014
Best of ASH 2014
Prof Simon Rule, Prof Antonio Palumbo, Prof Peter Hillmen, Prof Gert Ossenkoppel...
Best of ASH 2014 ( Prof Simon Rule, Prof Antonio Palumbo, Prof Peter Hillmen, Prof Gert Ossenkoppele )
8 Dec 2014
ASH 2014: Highlights in CLL from ASH 2014
Prof Peter Hillmen, Prof Clemens Wendtner, Prof Ulrich Jäger
ASH 2014: Highlights in CLL from ASH 2014 ( Prof Peter Hillmen, Prof Clemens Wendtner, Prof Ulrich Jäger )
8 Dec 2014
Oprozomib shows potential in the treatment of multiple myeloma
Dr Ravi Vij - Washington University School of Medicine, St Louis, USA
Oprozomib shows potential in the treatment of multiple myeloma ( Dr Ravi Vij - Washington University School of Medicine, St Louis, USA )
8 Dec 2014
Busulfan exposure dose tested for MDS and AML
Dr Ravi Vij - Washington University School of Medicine, St Louis, USA
Busulfan exposure dose tested for MDS and AML ( Dr Ravi Vij - Washington University School of Medicine, St Louis, USA )
8 Dec 2014
Ibrutinib as a single agent and in combination with dexamethasone showed anti-tu...
Dr Ravi Vij - Washington University School of Medicine, St Louis, USA
Ibrutinib as a single agent and in combination with dexamethasone showed anti-tumour activity in multiple myeloma ( Dr Ravi Vij - Washington University School of Medicine, St Louis, USA )
8 Dec 2014
Hope for avoiding chemo in patients with Hodgkins lymphoma
Prof Massimo Federico - University of Modena and Reggio Emilia, Modena, Italy
Hope for avoiding chemo in patients with Hodgkins lymphoma ( Prof Massimo Federico - University of Modena and Reggio Emilia, Modena, Italy )
8 Dec 2014
Combination therapy for high-risk MDS? Not quite yet
Dr Mikkael Sekeres - Cleveland Clinic, Cleveland, USA
Combination therapy for high-risk MDS? Not quite yet ( Dr Mikkael Sekeres - Cleveland Clinic, Cleveland, USA )
8 Dec 2014
Should young adults with acute lymphocytic leukaemia receive paediatric treatmen...
Dr Wendy Stock - University of Chicago, Chicago, USA
Should young adults with acute lymphocytic leukaemia receive paediatric treatment protocols? ( Dr Wendy Stock - University of Chicago, Chicago, USA )
8 Dec 2014
Results of HD2000 trial comparing combination therapies in advanced-stage Hodgki...
Prof Massimo Federico - University of Modena and Reggio Emilia, Modena, Italy
Results of HD2000 trial comparing combination therapies in advanced-stage Hodgkin's lymphoma ( Prof Massimo Federico - University of Modena and Reggio Emilia, Modena, Italy )
8 Dec 2014
Characterising the findings of the peripheral T-cell lymphoma registry
Prof Massimo Federico - University of Modena and Reggio Emilia, Modena, Italy
Characterising the findings of the peripheral T-cell lymphoma registry ( Prof Massimo Federico - University of Modena and Reggio Emilia, Modena, Italy )
8 Dec 2014
ASH 2014: Highlights in mantle cell lymphoma
Prof Steven Le Gouill and Prof Simon Rule
ASH 2014: Highlights in mantle cell lymphoma ( Prof Steven Le Gouill and Prof Simon Rule )
8 Dec 2014
ASH 2014: Highlights in multiple myeloma
Prof Philippe Moreau, Prof Keith Stewart, Prof Marivi Mateos, Prof Meletios Dimo...
ASH 2014: Highlights in multiple myeloma ( Prof Philippe Moreau, Prof Keith Stewart, Prof Marivi Mateos, Prof Meletios Dimopoulos )
8 Dec 2014
Tyrosine kinase inhibitor in combination with chemo shows benefit in acute myelo...
Dr Christoph Röllig - University Hospital Dresden, Dresden, Germany
Tyrosine kinase inhibitor in combination with chemo shows benefit in acute myeloid leukaemia ( Dr Christoph Röllig - University Hospital Dresden, Dresden, Germany )
7 Dec 2014
Chemo-free approach using IDH2 inhibitor shows positive response in acute myeloi...
Dr Eytan Stein - Memorial Sloan Kettering Cancer Center, New York, USA
Chemo-free approach using IDH2 inhibitor shows positive response in acute myeloid leukaemia ( Dr Eytan Stein - Memorial Sloan Kettering Cancer Center, New York, USA )
7 Dec 2014
New cytarabine combinations could overcome toxicities in AML treatment
Dr Farhad Ravandi - MD Anderson Cancer Center, Houston, USA
New cytarabine combinations could overcome toxicities in AML treatment ( Dr Farhad Ravandi - MD Anderson Cancer Center, Houston, USA )
7 Dec 2014
Paediatric leukaemia treatment regimens lead to improved outcomes in adolescents...
Dr Wendy Stock - University of Chicago, Chicago, USA
Paediatric leukaemia treatment regimens lead to improved outcomes in adolescents and young adults ( Dr Wendy Stock - University of Chicago, Chicago, USA )
7 Dec 2014
Targeted therapy effective in elderly patients with Philadelphia-positive acute ...
Dr Oliver Ottmann - Goethe University, Frankfurt, Germany
Targeted therapy effective in elderly patients with Philadelphia-positive acute lymphocytic leukaemia ( Dr Oliver Ottmann - Goethe University, Frankfurt, Germany )
7 Dec 2014
Children with rare leukaemia have better-than-expected outcomes after tailored t...
Dr Brent Wood - Seattle Children's Hospital, Seattle, USA
Children with rare leukaemia have better-than-expected outcomes after tailored treatment ( Dr Brent Wood - Seattle Children's Hospital, Seattle, USA )
7 Dec 2014
First randomised evidence for benefit from adding a tyrosine kinase inhibitor in...
Dr Christoph Röllig - University Hospital Dresden, Dresden, Germany
First randomised evidence for benefit from adding a tyrosine kinase inhibitor in acute myeloid leukaemia ( Dr Christoph Röllig - University Hospital Dresden, Dresden, Germany )
7 Dec 2014
Chemo-free treatment approach demonstrates positive responses in leukaemia patie...
Dr Eytan Stein - Memorial Sloan Kettering Cancer Center, New York, USA
Chemo-free treatment approach demonstrates positive responses in leukaemia patients ( Dr Eytan Stein - Memorial Sloan Kettering Cancer Center, New York, USA )
7 Dec 2014
Compound improves survival in aggressive acute myeloid leukaemia with manageable...
Dr Farhad Ravandi - MD Anderson Cancer Center, Houston, USA
Compound improves survival in aggressive acute myeloid leukaemia with manageable added toxicity in phase III trial ( Dr Farhad Ravandi - MD Anderson Cancer Center, Houston, USA )
7 Dec 2014
Blocking PD-1 activity could be safe and effective in classical Hodgkin lymphoma
Dr Phillippe Armand - Dana-Farber Cancer Institute, Boston, USA
Blocking PD-1 activity could be safe and effective in classical Hodgkin lymphoma ( Dr Phillippe Armand - Dana-Farber Cancer Institute, Boston, USA )
7 Dec 2014
Nivolumab shows early promise in Hodgkin lymphoma
Dr Phillippe Armand - Dana-Farber Cancer Institute, Boston, USA
Nivolumab shows early promise in Hodgkin lymphoma ( Dr Phillippe Armand - Dana-Farber Cancer Institute, Boston, USA )
7 Dec 2014
Blinatumomab demonstrates significant clinical activity in residual ALL
Dr Nicola Gökbuget - Goethe University Frankfurt, Frankfurt, Germany
Blinatumomab demonstrates significant clinical activity in residual ALL ( Dr Nicola Gökbuget - Goethe University Frankfurt, Frankfurt, Germany )
7 Dec 2014
New immunotherapy compound effective, safe in ALL patients with minimal residual...
Dr Nicola Gökbuget - Goethe University Frankfurt, Frankfurt, Germany
New immunotherapy compound effective, safe in ALL patients with minimal residual disease ( Dr Nicola Gökbuget - Goethe University Frankfurt, Frankfurt, Germany )
7 Dec 2014
T cell therapy leading to prolonged remission for children with aggressive leuka...
Dr Stephan Grupp - The Children's Hospital of Philadelphia, Philadelphia, USA
T cell therapy leading to prolonged remission for children with aggressive leukaemia ( Dr Stephan Grupp - The Children's Hospital of Philadelphia, Philadelphia, USA )
7 Dec 2014
Checkpoint inhibitors show safety and efficacy in Hodgkin lymphoma
Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA
Checkpoint inhibitors show safety and efficacy in Hodgkin lymphoma ( Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA )
7 Dec 2014
ASH 2014: Expert discussion on the latest in AML
Prof Alan Burnett and Prof Sergio Amadori
ASH 2014: Expert discussion on the latest in AML ( Prof Alan Burnett and Prof Sergio Amadori )
7 Dec 2014
Pembrolizumab may bring hope for patients with Hodgkin lymphoma
Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA
Pembrolizumab may bring hope for patients with Hodgkin lymphoma ( Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA )
7 Dec 2014
Immunology highlights from ASH 2014
Dr Catherine Bollard - George Washington University, Washington, USA
Immunology highlights from ASH 2014 ( Dr Catherine Bollard - George Washington University, Washington, USA )
7 Dec 2014
Comment: T cell therapy for children with aggressive leukaemia
Dr Catherine Bollard - George Washington University, Washington, USA
Comment: T cell therapy for children with aggressive leukaemia ( Dr Catherine Bollard - George Washington University, Washington, USA )
7 Dec 2014
Comment: Blinatumomab for acute lymphocytic leukaemia
Dr Catherine Bollard - George Washington University, Washington, USA
Comment: Blinatumomab for acute lymphocytic leukaemia ( Dr Catherine Bollard - George Washington University, Washington, USA )
7 Dec 2014
Comment: New PD-1 checkpoint inhibitors for treating Hodgkin lymphoma
Dr Catherine Bollard - George Washington University, Washington, USA
Comment: New PD-1 checkpoint inhibitors for treating Hodgkin lymphoma ( Dr Catherine Bollard - George Washington University, Washington, USA )
7 Dec 2014
ASH 2014: Expert discussion on the latest in CLL
Prof John Gribben and Prof Stephan Stilgenbauer
ASH 2014: Expert discussion on the latest in CLL ( Prof John Gribben and Prof Stephan Stilgenbauer )
7 Dec 2014
Engineering stem cell resistance to HIV for two-pronged approach to HIV-associat...
Prof Amrita Krishnan - City of Hope National Medical Center, Los Angeles, USA
Engineering stem cell resistance to HIV for two-pronged approach to HIV-associated lymphoma ( Prof Amrita Krishnan - City of Hope National Medical Center, Los Angeles, USA )
7 Dec 2014
Anti-CD38 antibody SAR may be new "blockbuster" treatment for aggressive multipl...
Dr Thomas Martin, MD, University of California, San Francisco, USA
Anti-CD38 antibody SAR may be new "blockbuster" treatment for aggressive multiple myeloma ( Dr Thomas Martin, MD, University of California, San Francisco, USA )
7 Dec 2014
Investigational antibody demonstrates efficacy, safety for patients with aggress...
Dr Thomas Martin, MD, University of California, San Francisco, USA
Investigational antibody demonstrates efficacy, safety for patients with aggressive multiple myeloma in phase I study ( Dr Thomas Martin, MD, University of California, San Francisco, USA )
7 Dec 2014
HIV-associated lymphoma responds well to stem cell transplantation
Dr Joe Alvarnas - City of Hope National Medical Center, Los Angeles, USA
HIV-associated lymphoma responds well to stem cell transplantation ( Dr Joe Alvarnas - City of Hope National Medical Center, Los Angeles, USA )
7 Dec 2014
Relapsed multiple myeloma responds to combination therapy with daratumumab
Prof Marivi Mateos - University Hospital of Salamanca, Salamanca, Spain
Relapsed multiple myeloma responds to combination therapy with daratumumab ( Prof Marivi Mateos - University Hospital of Salamanca, Salamanca, Spain )
7 Dec 2014
Daratumumab plus standard treatment improves outcomes in relapsed, hard-to-treat...
Prof Marivi Mateos - University Hospital of Salamanca, Salamanca, Spain
Daratumumab plus standard treatment improves outcomes in relapsed, hard-to-treat multiple myeloma in phase I study ( Prof Marivi Mateos - University Hospital of Salamanca, Salamanca, Spain )
7 Dec 2014
Stem cell transplantation safe for patients with HIV-associated lymphoma
Dr Joe Alvarnas - City of Hope National Medical Center, Los Angeles, USA
Stem cell transplantation safe for patients with HIV-associated lymphoma ( Dr Joe Alvarnas - City of Hope National Medical Center, Los Angeles, USA )
7 Dec 2014
Carfilzomib represents potent, effective addition to standard multiple myeloma t...
Prof Keith Stewart - Mayo Clinic, Scottsdale, USA
Carfilzomib represents potent, effective addition to standard multiple myeloma therapy in phase III study ( Prof Keith Stewart - Mayo Clinic, Scottsdale, USA )
7 Dec 2014
Post-transplant survival boosted by brentuximab vedotin in lymphoma
Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA
Post-transplant survival boosted by brentuximab vedotin in lymphoma ( Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA )
7 Dec 2014
Brentuximab vedotin prolongs post-transplant survival in hard-to-treat lymphoma ...
Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA
Brentuximab vedotin prolongs post-transplant survival in hard-to-treat lymphoma patients in phase III study ( Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA )
7 Dec 2014
Children with aggressive leukaemia experiencing remission with T cell therapy
Dr Stephan Grupp - The Children's Hospital of Philadelphia, Philadelphia, USA
Children with aggressive leukaemia experiencing remission with T cell therapy ( Dr Stephan Grupp - The Children's Hospital of Philadelphia, Philadelphia, USA )
7 Dec 2014
ASPIRE study: Carfilzomib potent addition to multiple myeloma therapy
Prof Keith Stewart - Mayo Clinic, Scottsdale, USA
ASPIRE study: Carfilzomib potent addition to multiple myeloma therapy ( Prof Keith Stewart - Mayo Clinic, Scottsdale, USA )
6 Dec 2014